Zhao CC, Zhan MN, Liu WT, Jiao Y, et al. Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer. Cancer Lett 2020 Aug 20. pii: S0304-3835(20)30419.
PMID: 32829006